Processing of prosomatostatin. 1990

R Benoit, and F Esch, and H P Bennett, and N Ling, and M Ravazzola, and L Orci, and E J Mufson
Montreal General Hospital, Quebec, Canada.

Several peptides are generated from prosomatostatin (proSS) in addition to somatostatin-14 (SS-14) and somatostatin-28 (SS-28). These are SS-28(1-12), proSS(1-76) and, as shown more recently, proSS(1-63) and antrin. Important variations in the proportion of these molecular forms are seen among different tissues and among different species. Processing of the precursor in the human brain yields minimal quantities of SS-28(1-12) and high levels of proSS(1-76), namely in cortical areas and in the bed nucleus of the stria terminalis. This is in contrast with findings in rat brain, where SS-28(1-12) is a predominant molecular form. Antrin, which corresponds to proSS(1-10), reaches its highest concentration in the antral portion of the stomach (117 +/- 13 pmol/g wet weight), where it is found in secretory granules of delta cells. We observed an inverse relationship between levels of antrin and proSS(1-63) after chromatography of various tissue extracts. This suggests a precursor-product relationship between these two peptides.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011498 Protein Precursors Precursors, Protein
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone

Related Publications

R Benoit, and F Esch, and H P Bennett, and N Ling, and M Ravazzola, and L Orci, and E J Mufson
July 1995, The Biochemical journal,
R Benoit, and F Esch, and H P Bennett, and N Ling, and M Ravazzola, and L Orci, and E J Mufson
February 1988, Biochemical and biophysical research communications,
R Benoit, and F Esch, and H P Bennett, and N Ling, and M Ravazzola, and L Orci, and E J Mufson
January 1988, Pancreas,
R Benoit, and F Esch, and H P Bennett, and N Ling, and M Ravazzola, and L Orci, and E J Mufson
February 1986, FEBS letters,
R Benoit, and F Esch, and H P Bennett, and N Ling, and M Ravazzola, and L Orci, and E J Mufson
May 1983, The Journal of biological chemistry,
R Benoit, and F Esch, and H P Bennett, and N Ling, and M Ravazzola, and L Orci, and E J Mufson
August 1998, The Biochemical journal,
R Benoit, and F Esch, and H P Bennett, and N Ling, and M Ravazzola, and L Orci, and E J Mufson
February 1994, Danish medical bulletin,
R Benoit, and F Esch, and H P Bennett, and N Ling, and M Ravazzola, and L Orci, and E J Mufson
April 1989, Cell,
R Benoit, and F Esch, and H P Bennett, and N Ling, and M Ravazzola, and L Orci, and E J Mufson
April 1981, Lancet (London, England),
R Benoit, and F Esch, and H P Bennett, and N Ling, and M Ravazzola, and L Orci, and E J Mufson
January 1995, Ciba Foundation symposium,
Copied contents to your clipboard!